Research ExplorerPublicationsUsp18 Expression in CD169+ Macrophages is Important for Stro...

Usp18 Expression in CD169+ Macrophages is Important for Strong Immune Response after Vaccination with VSV-EBOV

Standard

Usp18 Expression in CD169+ Macrophages is Important for Strong Immune Response after Vaccination with VSV-EBOV. / Friedrich, Sarah-Kim; Schmitz, Rosa; Bergerhausen, Michael; Lang, Judith; Cham, Lamin B; Duhan, Vikas; Häussinger, Dieter; Hardt, Cornelia; Addo, Marylyn; Prinz, Marco; Asano, Kenichi; Lang, Philipp Alexander; Lang, Karl Sebastian.

In: VACCINES-BASEL, Vol. 8, No. 1, 23.03.2020.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Friedrich, S-K, Schmitz, R, Bergerhausen, M, Lang, J, Cham, LB, Duhan, V, Häussinger, D, Hardt, C, Addo, M, Prinz, M, Asano, K, Lang, PA & Lang, KS 2020, 'Usp18 Expression in CD169+ Macrophages is Important for Strong Immune Response after Vaccination with VSV-EBOV', VACCINES-BASEL, vol. 8, no. 1. https://doi.org/10.3390/vaccines8010142

APA

Friedrich, S-K., Schmitz, R., Bergerhausen, M., Lang, J., Cham, L. B., Duhan, V., Häussinger, D., Hardt, C., Addo, M., Prinz, M., Asano, K., Lang, P. A., & Lang, K. S. (2020). Usp18 Expression in CD169+ Macrophages is Important for Strong Immune Response after Vaccination with VSV-EBOV. VACCINES-BASEL, 8(1). https://doi.org/10.3390/vaccines8010142

Vancouver

Friedrich S-K, Schmitz R, Bergerhausen M, Lang J, Cham LB, Duhan V et al. Usp18 Expression in CD169+ Macrophages is Important for Strong Immune Response after Vaccination with VSV-EBOV. VACCINES-BASEL. 2020 Mar 23;8(1). https://doi.org/10.3390/vaccines8010142

Bibtex

@article{0888d34d7cb542e787959987ea82c570,
title = "Usp18 Expression in CD169+ Macrophages is Important for Strong Immune Response after Vaccination with VSV-EBOV",
abstract = "Ebola virus epidemics can be effectively limited by the VSV-EBOV vaccine (Ervebo) due to its rapid protection abilities; however, side effects prevent the broad use of VSV-EBOV as vaccine. Mechanisms explaining the efficient immune activation after single injection with the VSV-EBOV vaccine remain mainly unknown. Here, using the clinically available VSV-EBOV vaccine (Ervebo), we show that the cell-intrinsic expression of the interferon-inhibitor Usp18 in CD169+ macrophages is one important factor modulating the anti-Ebola virus immune response. The absence of Usp18 in CD169+ macrophages led to the reduced local replication of VSV-EBOV followed by a diminished innate as well as adaptive immune response. In line, CD169-Cre+/ki x Usp18fl/fl mice showed reduced innate and adaptive immune responses against the VSV wildtype strain and died quickly after infection, suggesting that a lack of Usp18 makes mice more susceptible to the side effects of the VSV vector. In conclusion, our study shows that Usp18 expression in CD169+ macrophages is one important surrogate marker for effective vaccination against VSV-EBOV, and probably other VSV-based vaccines also.",
author = "Sarah-Kim Friedrich and Rosa Schmitz and Michael Bergerhausen and Judith Lang and Cham, {Lamin B} and Vikas Duhan and Dieter H{\"a}ussinger and Cornelia Hardt and Marylyn Addo and Marco Prinz and Kenichi Asano and Lang, {Philipp Alexander} and Lang, {Karl Sebastian}",
year = "2020",
month = mar,
day = "23",
doi = "10.3390/vaccines8010142",
language = "English",
volume = "8",
journal = "VACCINES-BASEL",
issn = "2076-393X",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

RIS

TY - JOUR

T1 - Usp18 Expression in CD169+ Macrophages is Important for Strong Immune Response after Vaccination with VSV-EBOV

AU - Friedrich, Sarah-Kim

AU - Schmitz, Rosa

AU - Bergerhausen, Michael

AU - Lang, Judith

AU - Cham, Lamin B

AU - Duhan, Vikas

AU - Häussinger, Dieter

AU - Hardt, Cornelia

AU - Addo, Marylyn

AU - Prinz, Marco

AU - Asano, Kenichi

AU - Lang, Philipp Alexander

AU - Lang, Karl Sebastian

PY - 2020/3/23

Y1 - 2020/3/23

N2 - Ebola virus epidemics can be effectively limited by the VSV-EBOV vaccine (Ervebo) due to its rapid protection abilities; however, side effects prevent the broad use of VSV-EBOV as vaccine. Mechanisms explaining the efficient immune activation after single injection with the VSV-EBOV vaccine remain mainly unknown. Here, using the clinically available VSV-EBOV vaccine (Ervebo), we show that the cell-intrinsic expression of the interferon-inhibitor Usp18 in CD169+ macrophages is one important factor modulating the anti-Ebola virus immune response. The absence of Usp18 in CD169+ macrophages led to the reduced local replication of VSV-EBOV followed by a diminished innate as well as adaptive immune response. In line, CD169-Cre+/ki x Usp18fl/fl mice showed reduced innate and adaptive immune responses against the VSV wildtype strain and died quickly after infection, suggesting that a lack of Usp18 makes mice more susceptible to the side effects of the VSV vector. In conclusion, our study shows that Usp18 expression in CD169+ macrophages is one important surrogate marker for effective vaccination against VSV-EBOV, and probably other VSV-based vaccines also.

AB - Ebola virus epidemics can be effectively limited by the VSV-EBOV vaccine (Ervebo) due to its rapid protection abilities; however, side effects prevent the broad use of VSV-EBOV as vaccine. Mechanisms explaining the efficient immune activation after single injection with the VSV-EBOV vaccine remain mainly unknown. Here, using the clinically available VSV-EBOV vaccine (Ervebo), we show that the cell-intrinsic expression of the interferon-inhibitor Usp18 in CD169+ macrophages is one important factor modulating the anti-Ebola virus immune response. The absence of Usp18 in CD169+ macrophages led to the reduced local replication of VSV-EBOV followed by a diminished innate as well as adaptive immune response. In line, CD169-Cre+/ki x Usp18fl/fl mice showed reduced innate and adaptive immune responses against the VSV wildtype strain and died quickly after infection, suggesting that a lack of Usp18 makes mice more susceptible to the side effects of the VSV vector. In conclusion, our study shows that Usp18 expression in CD169+ macrophages is one important surrogate marker for effective vaccination against VSV-EBOV, and probably other VSV-based vaccines also.

U2 - 10.3390/vaccines8010142

DO - 10.3390/vaccines8010142

M3 - SCORING: Journal article

C2 - 32210083

VL - 8

JO - VACCINES-BASEL

JF - VACCINES-BASEL

SN - 2076-393X

IS - 1

ER -